Ovid Therapeutics Inc

Ovid Therapeutics Inc. a biopharmaceutical company engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat a novel cholesterol 24 hydroxylase inhibitor which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329 a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350 a small molecule direct activator of the KCC2 transporter which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815 currently under preclinical stage that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV825 currently under preclinical stage which has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882 currently under preclinical stage a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx AstraZeneca AB H. Lundbeck A/S and Northwestern University as well as Marinus Pharmaceuticals Inc. The company was incorporated in 2014 and is headquartered in New York New York.